Preoperative and postoperative adjuvant chemotherapy for colorectal cancer - Results of 5-year survival using UFT. A pilot study

One hundred and eighty five of the histologically confirmed colorectal cancer patients were entered in this study. Patients were divided into two groups with or without preoperative chemotherapy of UFT, at a dose of 600 mg/day, for over 10 days before operation. After the operation, histologically curatively resected patients were divided again into two groups with or without postoperative adjuvant chemotherapy using UFT, at a dose of 400 mg/day, for one year after the operation. As the results, out of 137 curatively resected patients 68 patients were treated preoperatively and the average total doses of UFT were 7.91 g. There was no significant difference at five year survival and the disease free interval between with and without preoperative chemotherapy. Seventy-one patients received postoperative adjuvant chemotherapy and there was no significant difference in the colon cancer between with and without post operative adjuvant chemotherapy, but in the rectal cancer, the five year disease free interval with postoperative adjuvant chemotherapy was significant better than those without adjuvant chemotherapy group (90.0% vs 61.5%, G-W test p = 0.0243, p < 0.05).